Experimental dual-secretagogue formulation combining CJC-1295 No DAC with ipamorelin
PRODUCT PROFILE
CJC-1295 No DAC + Ipamorelin
Price range: £59.99 through £79.99
CJC-1295 No DAC + Ipamorelin is experimental dual-secretagogue formulation combining CJC-1295 No DAC with ipamorelin. Researchers examine it in relation to short-duration GHRH-receptor and ghrelin-receptor signalling at the pituitary.
Why it is distinct
It combines two complementary upstream receptor pathways without the albumin-binding DAC group that makes CJC-1295 DAC long acting.
- Evidence stageEarly human evidence
- AvailabilityAvailable · select size for stock
- Batch recordOpen COA
- DispatchConfirmed at checkout
SUGGESTED ADD-ONS
Useful additions, clearly shown.
Suggestions are organised by vial format and catalogue context. They are not combined-use guidance or personal-use advice.
-
Specification review
Bacteriostatic Water
Price range: £4.49 through £8.9910 mL | 3 mLBatch file pendingA laboratory supply with two volume variants, not a peptide or biologically active comparison material.
Available · select size for stockAdd to basket This product has multiple variants. The options may be chosen on the product page -
Preclinical
BPC-157
£32.99Batch COA availableBPC-157 is mainly discussed around stomach and local tissue-repair models. TB-500 is instead studied for actin, cell movement…
Available · 30 in stockAdd to basket -
Preclinical
TB-500
£32.99Batch COA availableTB-500 is discussed as a fragment-like repair material, while thymosin beta-4 is the full natural protein and BPC-157…
Available · 30 in stockAdd to basket
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
CJC-1295 No DAC + Ipamorelin is experimental dual-secretagogue formulation combining CJC-1295 No DAC with ipamorelin. Researchers examine it in relation to short-duration GHRH-receptor and ghrelin-receptor signalling at the pituitary.
Research focus+
CJC-1295 No DAC acts through the body’s growth-hormone-releasing pathway, while ipamorelin uses a ghrelin-related pathway. Evidence for the exact combination and its long-term safety is limited.
How the mechanism differs+
CJC-1295 No DAC acts through GHRH receptors, while ipamorelin acts through the ghrelin/GHSR-1a receptor; both converge on growth-hormone release through different upstream receptors.
Evidence and limitations+
Early human pharmacology exists for related secretagogues and CJC compounds, but controlled outcome and long-term safety evidence for this exact combination is limited. It is not an authorised combined medicine.
Testing and batch documentation+
Verified batch documents are available for review.
RESEARCH PROFILE
Understand the distinction.
CJC-1295 No DAC acts through the body’s growth-hormone-releasing pathway, while ipamorelin uses a ghrelin-related pathway. Evidence for the exact combination and its long-term safety is limited.
CJC-1295 No DAC acts through GHRH receptors, while ipamorelin acts through the ghrelin/GHSR-1a receptor; both converge on growth-hormone release through different upstream receptors.
It combines two complementary upstream receptor pathways without the albumin-binding DAC group that makes CJC-1295 DAC long acting.
Early human pharmacology exists for related secretagogues and CJC compounds, but controlled outcome and long-term safety evidence for this exact combination is limited. It is not an authorised combined medicine.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Early human evidence
CJC-1295 No DAC
Price range: £25.99 through £32.995 mgBatch COA availableShort-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page -
Established
Sermorelin
£49.005 mgBatch COA availableClosest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
UnavailableAsk about availability -
Early human evidence
GHRP-2
£44.005 mgBatch COA availableTypically characterised as a strong GH secretagogue with less appetite emphasis than GHRP-6.
UnavailableAsk about availability -
Experimental
PEG-MGF
£61.002 mgBatch COA availableA modified splice-variant fragment rather than a direct full IGF-1 receptor analogue.
UnavailableAsk about availability